Zobrazeno 1 - 10
of 72
pro vyhledávání: ''
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Berzosertib (formerly M6620) is the first-in-class inhibitor of ataxia–telangiectasia and Rad3-related protein, a key component of the DNA damage response, and being developed in combination with chemotherapy for the treatment of patients w
Autor:
Long Yang, Zilin Cui, Jiancun Hou, Rui Shi, Yang Li, Zheyue Yuan, Qing Tian, Xiaolong Liu, Zirong Liu, Jian Wang, Yamin Zhang, Lianjiang Wang
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:125-134
The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has
Autor:
Taira Hada, Hiroaki Soyama, Soichiro Kakimoto, Takahiro Sakamoto, Hiroko Matsuura, Jin Suminokura, Morikazu Miyamoto, Hideki Iwahashi, Masashi Takano, Hiroki Ishibashi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:941-947
The aim of this study was to investigate the association between changes in the levels of vascular endothelial growth factors (VEGFs) after treatment with bevacizumab and gemcitabine (Bev-Gem) and the clinical outcome.Platinum-resistant ovarian cance
Autor:
Michael A. Maddaus, Mark N. Kirstein, Abeer F. Alharbi, Robert A. Kratzke, Kinjal Sanghavi, Jonathan D'Cunha
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:387-391
PURPOSE: We investigated the safety, pharmacokinetics, and efficacy of gemcitabine administered via bronchial artery infusion (BAI) and IV infusion in advanced NSCLC patients. METHODS: Patients were eligible if they had received at least two prior cy
Autor:
Ichiro Kinoshita, Masaharu Nishimura, Jun Sakakibara-Konishi, K. Ito, Noriaki Sukoh, Masao Harada, Satoshi Fuke, Kosuke Nakano, Shinichi Fukumoto, Hiroshi Isobe, Satoshi Oizumi, Yutaka Nishigaki, Toraji Amano, Hirotoshi Dosaka-Akita, Toshiyuki Harada, Kenji Akie, Kei Takamura, Yuka Fujita
Publikováno v:
Cancer chemotherapy and pharmacology. 86(1)
This study evaluated the efficacy and safety of platinum plus gemcitabine (P/G) combinations as postoperative adjuvant chemotherapies for non-small cell lung cancer. Patients with postoperative stage IB–IIIA non-small cell lung cancer were randomly
Autor:
Kiyoshi Yoshino, Takeshi Yokoi, Ruriko Nakae, Tadashi Kimura, Masami Fujita, Masahiko Takemura, Shoji Kamiura, Tateki Tsutsui, Takuji Tomimatsu, Kazushige Adachi, Eiji Kobayashi, Seiji Mabuchi, Kenjiro Sawada, Yasuhiko Shiki, Yutaka Ueda, Kae Hashimoto, A. Wakimoto, Takamichi Nishizaki, Yuki Kanda
Publikováno v:
Cancer Chemotherapy and Pharmacology. 80:1239-1247
To develop a new therapeutic strategy for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancers, we evaluated the feasibility and efficacy of irinotecan and gemcitabine combination chemotherapy.Patients with taxane/platinum-resi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 79:995-1001
There is little information on tolerability to cisplatin-based chemotherapies in patients with a solitary kidney after nephroureterectomy. We evaluated the impact of having a solitary kidney on tolerability to gemcitabine plus cisplatin (GC) chemothe
Autor:
Seiji Yoshitomi, Takayuki Iwamoto, Junji Matsuoka, Takayuki Motoki, Toshiharu Mitsuhashi, Tomohiro Nogami, Taeko Mizoo, Hisashi Tsuji, Tadahiko Shien, Yutaka Ogasawara, Hiroyoshi Doihara, Naruto Taira
Publikováno v:
Cancer Chemotherapy and Pharmacology. 78:289-294
Gemcitabine (Gem) with paclitaxel (Pac) is used for patients with metastatic breast cancer who require cytoreduction with manageable toxicities. Nanoparticle albumin-bound (nab)-Pac exhibits better efficacy and reduces the risk of hypersensitivity re
Autor:
Richard C. Chao, E. Gabriela Chiorean, Peter J. O'Dwyer, Nashat Y. Gabrail, Thierry Alcindor, Emily Chan, Diane Potvin, Herbert Hurwitz
Publikováno v:
Cancer chemotherapy and pharmacology. 81(2)
To evaluate the safety and efficacy of mocetinostat (a Class I/IV HDAC inhibitor) in combination with gemcitabine in patients with solid tumors, including pancreatic cancer. In this open-label, non-randomized Phase I/II study (NCT00372437) sequential
Autor:
In Gab Jeong, Hanjong Ahn, Jun Hyuk Hong, Cheryn Song, Yi Rang Kim, Dalsan You, Jae-Lyun Lee, Bumsik Hong
Publikováno v:
Cancer Chemotherapy and Pharmacology. 76:141-153
Cisplatin-based chemotherapies are standard treatment regimens of advanced urothelial cell carcinoma. But a significant proportion of patients are unsuitable for cisplatin due to impaired renal function. Carboplatin-based regimens such as gemcitabine